Jos Buijs
Overview
Explore the profile of Jos Buijs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
390
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petersen I, Morrison J, Petrovic A, Babic N, Metzendorf N, Godec A, et al.
Sci Rep
. 2024 Dec;
14(1):30613.
PMID: 39715817
Transferrin Receptor (TfR)-mediated transcytosis across the blood-brain barrier (BBB) enables the uptake of bispecific therapeutic antibodies into the brain. At therapeutically relevant concentrations, bivalent binding to TfR appears to reduce...
2.
Perez-Ropero G, Perez-Rafols A, Martelli T, Danielson U, Buijs J
Biochemistry
. 2024 Oct;
63(21):2816-2829.
PMID: 39397705
The kinetics of the interaction between Musashi-1 (MSI1) and RNA have been characterized using surface plasmon resonance biosensor analysis. Truncated variants of human MSI1 encompassing the two homologous RNA recognition...
3.
Dolcemascolo R, Heras-Hernandez M, Goiriz L, Montagud-Martinez R, Requena-Menendez A, Ruiz R, et al.
Elife
. 2024 Feb;
12.
PMID: 38363283
The RNA recognition motif (RRM) is the most common RNA-binding protein domain identified in nature. However, RRM-containing proteins are only prevalent in eukaryotic phyla, in which they play central regulatory...
4.
Rofo F, Buijs J, Falk R, Honek K, Lannfelt L, Lilja A, et al.
Transl Neurodegener
. 2021 Sep;
10(1):38.
PMID: 34579778
Background: Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer's disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them...
5.
Bondza S, Marosan A, Kara S, Losing J, Peipp M, Nimmerjahn F, et al.
Front Immunol
. 2021 Jan;
11:609941.
PMID: 33505398
Monoclonal antibodies directed against the CD20 surface antigen on B cells are widely used in the therapy of B cell malignancies. Upon administration, the antibodies bind to CD20 expressing B...
6.
Bondza S, Ten Broeke T, Nestor M, Leusen J, Buijs J
MAbs
. 2020 Aug;
12(1):1792673.
PMID: 32744151
Based on their mechanism of action, two types of anti-CD20 antibodies are distinguished: Type I, which efficiently mediate complement-dependent cytotoxicity, and Type II, which instead are more efficient in inducing...
7.
Encarnacao J, Napolitano V, Opassi G, Danielson U, Dubin G, Popowicz G, et al.
FEBS Lett
. 2020 May;
594(15):2406-2420.
PMID: 32473599
The interaction between the Shiga toxin B-subunit (STxB) and its globotriaosylceramide receptor (Gb3) has a high potential for being exploited for targeted cancer therapy. The primary goal of this study...
8.
Regula N, Honarvar H, Lubberink M, Jorulf H, Ladjevardi S, Haggman M, et al.
Int J Med Sci
. 2020 Feb;
17(2):214-223.
PMID: 32038105
: Dynamic [C]-acetate positron emission tomography (PET) can be used to study tissue perfusion and carbon flux simultaneously. In this study, the feasibility of the quantification of prostate cancer aggressiveness...
9.
Brechmann N, Eriksson P, Eriksson K, Oscarsson S, Buijs J, Shokri A, et al.
Biotechnol Prog
. 2019 Jan;
35(3):e2775.
PMID: 30629859
High capacity magnetic protein A agarose beads, LOABeads PrtA, were used in the development of a new process for affinity purification of monoclonal antibodies (mAbs) from non-clarified CHO cell broth...
10.
Deyev S, Vorobyeva A, Schulga A, Proshkina G, Guler R, Lofblom J, et al.
Mol Pharm
. 2019 Jan;
16(3):995-1008.
PMID: 30608701
Designed ankyrin repeat proteins (DARPins) are small engineered scaffold proteins that can be selected for binding to desirable molecular targets. High affinity and small size of DARPins render them promising...